E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Prostate Cancer or Breast Cancer with Metastatic Bone Disease |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To estimate the effect of AZD0530 plus standard of care (SoC) compared with zoledronic acid plus SoC on bone resorption by assessment of serum beta Cterminal cross-linking telopeptide of Type I collagen (βCTx)
|
|
E.2.2 | Secondary objectives of the trial |
1. To investigate the safety and tolerability of AZD0530 in patients with either breast cancer or prostate cancer who have metastatic bone disease by assessment of Adverse Events (AEs), physical examination, blood pressure (BP), pulse, electrocardiogram (ECG), and laboratory findings 2. To estimate the effect of AZD0530 plus SoC on bone turnover (bone resorption and bone formation) by assessment of serum markers bone-specific alkaline phosphatase (bALP), N-terminal propeptide of Type I collagen (PINP), cross-linked C-terminal telopeptide of Type I collagen (ICTP), and tartrate-resistant acid phosphatase 5b (TRAP5b) and urine markers N-terminal cross-linking telopeptide of Type I collagen normalised to creatinine (NTx/Cr) and alpha-alpha C-terminal cross-linking telopeptide of Type I collagen normalised to creatinine (ααCTx/Cr) 3. To investigate the steady state pharmacokinetics (PK) of AZD0530 in this patient population by assessment of appropriate PK parameters
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Provision of signed, written informed consent 2. Age 18 years and older 3. Histologically or cytologically confirmed breast (female only) or prostate cancer 4. At least one radiographically confirmed metastatic bone lesion 5. No change of cancer therapy for at least 8 weeks before randomisation 6. Urinary NTx/Cr greater than or equal to 30 nmol BCE/mmol creatinine 7. World Health Organisation (WHO) performance status 0 to 2 8. Life expectancy of more than 12 weeks 9. Negative pregnancy test if female and of child-bearing potential
For inclusion in this exploratory biomarker research, patients must: 1. Provide informed consent for exploratory biomarker research
For inclusion in this genetic research, patients must: 1. Provide informed consent for genetic research
|
|
E.4 | Principal exclusion criteria |
1. Brain metastases or risk of spinal cord compression, unless treated at least 4 weeks before entry, and stable without steroid treatment for 1 week OR New neurological symptoms or signs consistent with acute or evolving spinal cord compression confirmed with magnetic resonance imaging (MRI) (stable, previously-treated patients are allowed) OR Other central nervous system metastatic involvement 2. Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count <1.5 x 10 to the power of 9/L or platelet count <100 x 10 to the power of 9/L 3. Haemoglobin ≤ 9g/dL (5.59 mMol/L) (blood transfusion permitted following discussion with AstraZeneca Study Physician) 4. Inadequate liver function as demonstrated by serum bilirubin ≥2 times the upper limits of reference range (ULRR) or by alanine aminotransferase (ALT), aspartate aminotransferase (AST) or ALP ≥2.5 times the ULRR (≥5 times the ULRR in the presence of liver metastases). If bone metastases are present and liver function is otherwise considered adequate by the investigator then elevated ALP will not exclude the patient. 5. Impaired renal function, defined by creatinine ≥1.5 times the ULRR or creatinine clearance of ≤ 50 mL/min determined by Cockcroft-Gault formula; or ≥ +2 proteinuria on 2 consecutive dipsticks taken no less than 24 hours apart 6. Any prior exposure to bisphosphonate therapy 7. Have a planned change in cancer therapy before completion of the 4 week treatment period 8. Have received in the previous 4 weeks any of the following: - cytotoxic chemotherapy - chemotherapy with novel, molecularly targeted agents 9. Are receiving, or have received in the previous 12 months, any of the following: - PTH/ PTH analogue - Vitamin D analogues (eg, calcitriol)/ treatment with Vitamin D at doses of 1200 IU or greater for a period of three months or more 10. Prior treatment with radiopharmaceuticals or radiotherapy to bone (focal radiotherapy of localised, non-target bone lesions would be permitted if completed up to 4 weeks prior to study entry) 11. Have had hip fractures or bilateral hip prosthesis, fracture of any kind, or surgery to bone within 12 months of randomisation 12. Evidence of severe or uncontrolled systemic conditions (eg, severe hepatic impairment, interstitial lung disease [bilateral, diffuse, parenchymal lung disease]) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardise compliance with the protocol 13. Pregnant or breast-feeding women 14. Unwillingness to use an acceptable method of contraception while on study (for women and men where female partner is of child bearing potential). (Postmenopausal status will be considered adequate evidence of non-childbearing potential and is defined as any 1 of the following: natural menopause with last menses >1 year ago; radiation induced oophorectomy with last menses >1 year ago. Women with prior bilateral oophorectomy or hysterectomy will also be considered not of childbearing potential). 15. Unresolved toxicity ≥ CTCAE grade 2 from previous anti-cancer therapy except alopecia 16. Resting ECG with measurable QTc interval of >480 msec at 2 or more time points within a 24 hour period of each other 17. Concomitant use of any medication or herbal supplement that may significantly modulate CYP3A4 activity or the activity of which is significantly modified by CYP3A4 (with special regard to those calcium channel antagonists that are CYP3A4 substrates). Such drugs must have been discontinued for approximately 2 weeks or more prior to starting the study medication except for pimozide, astemizole and amiodarone where the time interval to study entry will be 4, 8 and 12 weeks, respectively. See Appendix E for a list of warnings of possible drug interactions. 18. History of ischaemic heart disease with myocardial infarction within 3 months of study entry, symptomatic cardiac ischaemia or symptomatic congestive heart failure 19. Any other concurrent condition which in the investigator’s opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol 20. Patients believed to have a known immunodeficiency syndrome 21. Participation in another study with an investigational product within the previous 30 days or participation in a previous clinical study within 30 days prior to study entry 22. Risk (in the investigator’s opinion) of transmitting, through blood or other body fluids, the agents responsible for Acquired Immunodeficiency Syndrome, hepatitis B, or hepatitis C
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The absolute and percentage change from baseline in serum βCTX |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Information not present in EudraCT |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 9 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the study is defined as the time point after which no patient will be exposed to study related activities, including the 30 days follow up following study treatment.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 12 |